WANJIA GROUP HOLDINGS LIMITED Wanjia Group Holdings Limited Share Price
Equities
401
KYG9431A1186
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.063 HKD | 0.00% |
|
0.00% | -25.88% |
| 2023 | Wanjia Group Holdings Incurs Wider Loss in Fiscal H1 | MT |
| 2023 | Wanjia Group Holdings Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
| Sales 2022 | 155M 19.78M 1.58B | Sales 2023 | 174M 22.19M 1.78B | Capitalization | 101M 12.88M 1.03B |
|---|---|---|---|---|---|
| Net income 2022 | -51M -6.51M -522M | Net income 2023 | 1M 128K 10.23M | EV / Sales 2022 | 0.66 x |
| Net Debt 2022 | 18.72M 2.39M 191M | Net Debt 2023 | 15.29M 1.95M 156M | EV / Sales 2023 | 0.67 x |
| P/E ratio 2022 |
-1.65
x | P/E ratio 2023 |
55.4
x | Employees | 198 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72% |
More Fundamentals
* Assessed data
More news
| 3 months | -19.23% | ||
| 6 months | -19.23% | ||
| Current year | -25.88% |
1 week
0.05
0.06
1 month
0.050.08
Current year
0.050.09
1 year
0.050.18
3 years
0.050.28
5 years
0.050.55
10 years
0.0511.90
| Managers | Title | Age | Since |
|---|---|---|---|
Jia Jun Wang
CEO | Chief Executive Officer | 35 | 30/08/18 |
Sze Kin Tam
DFI | Director of Finance/CFO | 54 | 31/10/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Man Ho
BRD | Director/Board Member | 55 | 13/02/18 |
Yong Ping Liu
BRD | Director/Board Member | 69 | 26/02/14 |
Hon Kit Wong
BRD | Director/Board Member | 57 | 10/04/13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.063 | 0.00% | 0 |
| 25/04/24 | 0.063 | 0.00% | 0 |
| 24/04/24 | 0.063 | 0.00% | 620,000 |
| 23/04/24 | 0.063 | 0.00% | 0 |
| 22/04/24 | 0.063 | 0.00% | 256 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
Wanjia Group Holdings Ltd is an investment holding company principally engaged in the pharmaceutical wholesale and distribution business, and hemodialysis treatment and consultancy service business. The Company mainly operates its business through two segments. The Pharmaceutical Wholesale and Distribution Business segment mainly distributes pharmaceutical products for pharmaceutical retail chain stores, independent pharmacies and outpatient departments of community hospitals and healthcare service stations. The Hemodialysis Treatment and Consultancy Service Business segment mainly provides kidney care services and operates hemodialysis treatment centers.
Calendar
23/06/2024
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.88% | 4.51M | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +10.92% | 29.4B | |
| -12.71% | 16.73B | |
| -3.06% | 16.36B | |
| -2.63% | 14.92B | |
| -31.75% | 11.77B | |
| -1.42% | 11.72B | |
| +27.44% | 11.71B |
- Stock Market
- Equities
- 401 Stock
